Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 117,132 shares, a growth of 90.7% from the August 15th total of 61,410 shares. Based on an average trading volume of 34,578 shares, the days-to-cover ratio is presently 3.4 days. Approximately 0.3% of the company’s shares are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Estrella Immunopharma stock. BlackRock Inc. acquired a new stake in Estrella Immunopharma, Inc. (NASDAQ:ESLA) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 52,033 shares of the company’s stock, valued at approximately $54,000. BlackRock Inc. owned 0.12% of Estrella Immunopharma as of its most recent filing with the SEC. 0.35% of the stock is owned by hedge funds and other institutional investors.

Estrella Immunopharma Stock Performance

NASDAQ:ESLA traded down $0.02 during trading hours on Tuesday, hitting $0.61. 48,131 shares of the company’s stock traded hands, compared to its average volume of 100,725. The stock’s fifty day moving average price is $0.74 and its two-hundred day moving average price is $1.06. The firm has a market cap of $26.58 million, a P/E ratio of -2.55 and a beta of 0.88. Estrella Immunopharma has a twelve month low of $0.58 and a twelve month high of $3.15.

Estrella Immunopharma (NASDAQ:ESLA) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04. On average, equities research analysts predict that Estrella Immunopharma will post -0.25 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Estrella Immunopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Estrella Immunopharma presently has an average rating of “Hold” and an average price target of $8.00.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.